Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA expands Pfizer's Hympavzi label to hemophilia A and B patients aged 6 and older following Ph3 results
Antibody, hemophilia, monoclonal antibody, anti-TFPI, pediatric population, prophylactic treatment - Read more

Chiesi's Loxujta (lomitapide) gains EU paediatric label expansion for homozygous familial hypercholesterolaemia backed by Ph3 data
Small molecule, metabolic, MTP inhibitor, homozygous familial hypercholesterolaemia, paediatric - Read more

Sanofi's Sarclisa (isatuximab) wins EU approval as subcutaneous anti-CD38 formulation for multiple myeloma via on-body injector
Antibody, cancer, monoclonal antibody, multiple myeloma, CD38, subcutaneous delivery - Read more

GSK, Engitix partner on liver fibrosis regression research, £44.5M ($59.5M) upfront, £118M ($157.7M) milestones per target
Research collaboration, hepatology, drug discovery, extracellular matrix, milestone payments - Read more

Roche, Nurix Therapeutics partner on BTK degrader bexobrutideg for B cell malignancies, $700M upfront, $3B total
Co-development, oncology, protein degrader, small molecule, milestone payments, royalties - Read more

Sanofi, Owkin extend partnership from oncology discovery to AI agent development with five-year K Pro license
Licensing deal, oncology, AI/ML, drug discovery, R&D - Read more

Everest Medicines acquires LNZ100 rights from Corxel Pharmaceuticals for Greater China presbyopia development
Asset purchase agreement, ophthalmology, small molecule, milestone payments, commercialization - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Lundbeck's (bocunebart) Ph2 data support advancement targeting PACAP pathway for migraine prevention
Antibody, neurological, monoclonal antibody, migraine, PACAP inhibitor, chronic migraine - Read more

Amgen's Repatha (evolocumab) Ph3 data show cardiovascular risk reduction in high-risk diabetes patients without prior heart attack or stroke
Protein therapy, cardiovascular, monoclonal antibody, PCSK9 inhibitor, high-risk diabetes, LDL-C lowering - Read more

Dexcom's G7 continuous glucose monitor shows blood sugar benefit in non-insulin type 2 diabetes patients in Ph3 trial
Medical device, metabolic, continuous glucose monitor, type 2 diabetes, blood glucose management - Read more

Eli Lilly's retatrutide achieves 30.3% weight reduction at 104 weeks in Ph3 trial for obesity
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, type 2 diabetes, triple-G agonist - Read more

Pfizer advances (berobenatide) into Ph3 obesity program after Ph2 data show comparable efficacy to leading glucagon-like peptide-1 agents
Small molecule, metabolic, GLP-1 agonist, obesity, type 2 diabetes, combination therapy - Read more

Tango Therapeutics, Revolution Medicines' vopimetostat plus (daraxonrasib) combo achieves 92% response in Ph1/2 pancreatic ductal adenocarcinoma
Small molecule, cancer, PRMT5 inhibitor, RAS inhibitor, pancreatic ductal adenocarcinoma, MTAP deletion - Read more

Bayer's Kerendia (finerenone) Ph3 data supports label expansion for non-diabetic chronic kidney disease
Small molecule, cardiovascular, mineralocorticoid receptor antagonist, chronic kidney disease, finerenone, non-diabetic CKD - Read more

Roche shares Ph3 data for Gazyva (obinutuzumab) showing remission benefit in primary membranous nephropathy
Antibody, autoimmune, monoclonal antibody, primary membranous nephropathy, CD20, obinutuzumab - Read more

Sciwind Biosciences' (ecnoglutide) delivers 35% greater weight loss than semaglutide in Ph3 head-to-head obesity study
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, ecnoglutide vs semaglutide, cAMP-biased mechanism - Read more

Antag Therapeutics reports positive Ph1 results for AT7687 (at7687), first-in-class GIPR antagonist targeting obesity
Peptide therapy, metabolic, GIPR antagonist, obesity, combination therapy, insulin resistance - Read more

Dayspring Pharma's CG2001 (minoxidil/finasteride) meets Ph2 primary endpoint for male androgenetic alopecia treatment
Small molecule, dermatology, combination therapy, androgenetic alopecia, minoxidil, finasteride - Read more

Boehringer Ingelheim, Zealand's (survodutide) Ph3 shows visceral, liver fat reductions in obesity and metabolic dysfunction-associated steatotic liver disease
Protein therapy, metabolic, GLP-1/GIP agonist, obesity, MASLD, visceral fat reduction - Read more

Hikma Pharmaceuticals invests $267M to expand two Ohio manufacturing sites, adding 350 jobs
Small molecule, multiple disease areas, operational, major transaction - Read more

Johnson & Johnson acquires Firefly Bio for $1B upfront to access DAC platform targeting KRAS-driven tumors
Degrader antibody conjugate, oncology, major transaction, strategic - Read more

Incyte acquires Vega Therapeutics for up to $2B, adding Phase 3 blood disorder asset VGA039
Monoclonal antibody, rare disease, major transaction, strategic - Read more

ResMed acquires Noctrix Health for $340M, expanding sleep tech portfolio with restless legs syndrome device
Neuromodulation device, sleep disorder, major transaction, strategic - Read more

Treeline Biosciences merges with Standard BioTools via reverse merger to pursue Nasdaq listing with $900M cash
Small molecule, oncology, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA investigates mifepristone safety amid pro-life pressure on Trump, potential restrictions ahead
Small molecule, women's health, regulatory, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here